Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.

Combined tobacco and e-cigarette exposure linked to increase in activity-related symptoms, nighttime symptoms, albuterol use.

Net decreases in prevalence seen across age groups, with largest relative reduction for young adults aged 18 to 29 years.

Pivotal adult trial data support planned BLA submission for Vaxcyte's investigational 31-valent pneumococcal conjugate vaccine candidate.

Epcoritamab combined with R-CHOP significantly improved progression free survival in patients with newly diagnosed DLBCL across both the primary endpoint and total populations.

The estimated 5-year risk for the renal outcome was 2.4 vs 2.1% for people taking GLP-1 receptor agonists or SGLT-2 inhibitors vs those taking DPP-4 inhibitors. HealthDay News — For adults with type 2 ...

HealthDay News — Nearly 1 in 5 patients report encountering ophthalmic treatments they perceive as bogus, according to a research letter published online September 24 in JAMA Ophthalmology.

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...